Specific antibody titers against various infectious agents in polyspecific human immunoglobulin preparations
|
|
- Jeremy Tucker
- 5 years ago
- Views:
Transcription
1 Specific antibody titers against various infectious agents in polyspecific human immunoglobulin preparations Global Bio Conference 2018 Hye-Kyung Cho Department of Pediatrics, Gachon University College of Medicine, Gil Medical Center, Incheon, Republic of Korea
2 Contents Characteristics of immunoglobulin preparations Indication of IG use in infectious diseases Standards of antibody potency Declining antibody titer in plasma pool Changes on prophylatic dosage of IG
3 Contents Characteristics of immunoglobulin preparations Indication of IG use in infectious diseases Standards of antibody potency Declining antibody titer in plasma pool Changes on prophylatic dosage of IG
4 Immunoglobulin preparations Derived from pooled plasma of adults Primarily of the immunoglobulin (Ig) fraction (at least 90% IgG and trace amounts of IgA and IgM) IMIG is a concentrated protein solution (approximately 16.5% or 165 mg/ml) IVIG is available as a lyophilized powder or as a formulated liquid solution, with final concentrations of IgG ranging from 3% to 12%, depending on the product.
5 Antibodies included in IG preparations Derived from pooled plasma of healthy donors 1,000 to 60,000 per lot of final product Include broad spectrum of antibodies Supply a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents, and their toxins
6 Classification of IG products Formulation by type of antibody desired, donor Polyspecific (polyvalent) IG Specific (hyperimmune) IG: eg., HBIG, VZIG, HRIG, TIG, Formulation by route of administration IVIG (intravenous) IMIG (intramuscular) SCIG (subcutaneous)
7 Contents Characteristics of immunoglobulin preparations Indication of IG use in infectious diseases Standards of antibody potency Declining antibody titer in plasma pool Changes on prophylatic dosage of IG
8 Indications of IG use in infectious diseases Replacement therapy in antibody-deficiency disorders Prophylaxis against some viral infections Proven beneficial only for measles, varicella, hepatitis A, hepatitis B Treatment of some infectious diseases AAP. Redbook 30 th ed, 2015 Looney RJ et al. Best Pract Res Clin Haematol. 2006
9 Primary Immunodeficiencies Antibody-mediated Immune deficiency Cell-mediated Immune deficiency Combined immune deficiency Phagocytic deficiency Complement deficiency Complement 2% Phagocytic Cellular 18% Antibody 10% 50% Others Combined 20% The overall prevalence of PID is about 1:100,000
10 Primary immunodeficiencies: Ab deficiencies Disorder Gene (if known) IgG replacement indicated? IVIG every 3 4 weeks are effective in preventing serious Agammaglobulinemia bacterial infections. X-linked agammaglobulinemia Btk Yes μ heavy chain deficiency IGHM Yes Lifelong IVIG treatment should be needed. Igα deficiency CD79A Yes Igβ deficiency CD79B Yes B-cell linker protein BLNK Yes Common variable immune deficiency Immune co-stimulator protein ICOS Yes CD19 deficiency CD19 Yes CD20 deficiency CD20 Yes TACI deficiency TNFRSF13B Yes BAFF receptor deficiency TNFRSF13C Yes CVID Unknown Yes Kobrynski L. Biologics 2012
11 Primary immunodeficiencies: Ab deficiencies Disorder Gene (if known) IgG replacement indicated? Other antibody deficiencies Selective IgA deficiency Unknown No IgG subclass deficiency Unknown If recurrent infections Specific antibody deficiency Transient hypogammaglobulinemia of infancy Other PIDD with antibody deficiency Unknown Unknown Hyper-IgM syndrome (X-linked) CD40L Yes (AR) AID, UNG Yes Severe combined immune deficiency Various Yes Wiskott Aldrich syndrome WASP Yes To ensure IG potency in the PI patients is crucial! Ataxia-telangiectasia syndrome ATM Yes Reticular dysgenesis AK2 Yes DiGeorge syndrome 22q11.2/10p13 deletion Only for patients with low IgG Kobrynski L. Biologics 2012
12 Contents 1 Characteristics of immunoglobulin preparations Indication of IG use in infectious diseases Standards of antibody potency Declining antibody titer in plasma pool Changes on prophylatic dosage of IG
13 U.S. FDA regulations on antibody potency of IG products (CFR 21) Antibody levels and tests Each lot of final product shall contain at least the minimum levels of antibodies for diphtheria, measles, and for at least one type of poliomyelitis. Minimum antibody levels No less than 2 units of diphtheria antitoxin per ml. Measles neutralizing antibody level, compared with that of a reference material designated by the Center for Biologics Evaluation and Research (CBER), FDA Poliomyelitis Type 1, Type 2, or Type 3 neutralizing antibody level, compared with that of a reference material
14 European regulations on antibody potency of IG products Product specific for SC/IMIG with a minimum antibody content for Hepatitis A virus of 100 IU/ml No recommended routine measurement for measles antibody EMEA. Guideline on Core SPC for Human Normal Immunoglobulin for Subcutaneous and Intramuscular Use 2015.
15 Antibodies included in IG preparations The production of protective antibodies in human plasma is initiated via vaccination or natural exposure. Changes on epidemiology of various infectious diseases and herd immunity Improvements in sanitation and socioeconomic conditions, widespread use of vaccines, high immunization rate Decreased natural boosting from exposure to wild-type pathogens Limitation to maintain protective antibody level, possible waning immunity
16 Contents 1 Characteristics of immunoglobulin preparations Indication of IG use in infectious diseases Standards of antibody potency Declining antibody titer in plasma pool Changes on prophylatic dosage of IG
17 Potency of measles neutralizing antibodies in 7 IGIV products manufactured IVIG from Source Plasma (white bars), IVIG from recovered plasma (shaded bars) *P <.05, compared with US Reference IG (US Ref IG); **P <.05, for comparison of the 2 donor groups. Audet S, et al. JID 2006;194:781-9.
18 Global reported measles cases and estimated coverage with the first and second dose of measles-containing vaccine by year ( ) Rota PA et al. Nat Rev Dis Primers Jul
19 Vaccine-induced Ab vs. Natural infection-derived Ab Abs derived from vaccines are lower in level and shorter in duration than antibodies obtained from natural infection. IgG avidity and IgG antibody levels, important parameters of the quality of humoral immune response, are lower after vaccination than after primary infection. Recent infection IgG avidity IgG avidity IgG level Recent vaccination IgG level (A) Anti-rubella Ab kinetics for recent vaccination (B) for recent primary rubella virus infection Vauloup-Fellous C, Grangeot-Keros L. Clin Vaccine Immunol 2007
20 Ab level in plasma pool Declining antibody titer in plasma pool Before the measles vaccine was introduced in 1963 (1965 in Korea), the general population was exposed to measles naturally, resulting in a high level of antibodies for the disease. Natural exposure Vaccination 1960 s time
21 Contents 1 Characteristics of immunoglobulin preparations Indication of IG use in infectious diseases Standards of antibody potency Declining antibody titer in plasma pool Changes on prophylatic dosage of IG
22 Measles High fever and rash 3C (cough, coryza, conjunctivitis) Very contagious Airborne transmission Measles vaccines: WHO position paper April 2017
23 Disease burden of measles The global annual reported measles incidence declined by 75% during ; from 146 to 35 cases per million population Estimated 134,200 measles deaths globally in 2015 Estimated 7 million people affected by measles in 2016 Case fatality: <0.01% in industrialized countries, >5% in developing countries Measles vaccines: WHO position paper April 2017 Rota PA et al. Nat Rev Dis Primers Jul
24 Post-exposure prophylaxis (PEP) against measles Use of vaccine if given within 72 hours of measles exposure to susceptible individuals, will provide protection or disease modification in some cases Use of Immunoglobulin Can be administered either IM or IV within 6 days of exposure to prevent or modify measles should be given as soon as possible after exposure IG should be considered for susceptible pregnant women susceptible immunocompromised contacts of measles children less than 6 months of age AAP. Redbook 30 th ed, 2015
25 IG for measles post-exposure prophylaxis : Japan experience 33 unvaccinated infants given IGIM (0.33 ml/kg) within 5 days of measles exposure ( >1 h in same room) Neutralizing antibody concentrations determined in IGIM lots Measles attack rates were: 8/14 (57%) among infants given IGIM with 16 IU/mL (5.28 IU/kg) 1/6 (17%) among infants given IGIM with 33 IU/mL (10.89 IU/kg) 0/13 (0%) among those given IGIM with 40 or 45 IU/mL (13.2 IU/kg) Protected children received a mean dose of 10.9 IU/kg compared to 5.7 IU/kg for whom PEP failed. Endo A, et al. J Pediatr. 2001;138:926-8.
26 Lowering measles specification for IVIG/SCIG Evidence for declining antibody titers Concern for supply failure of release testing results in rejection of IVIG/SCIG lot Concern for primary immunodeficiency patients will protective titers be achieved? 2007, U.S. FDA, Blood Products Advisory Committee IVIG/SCIG, 0.60 x CBER 0.48 x CBER * IMIG, 0.60 x CBER standard
27 Calculated serum measles-neutralizing Ab (mnab) concentration following IG PEP IG Product (Dose) IGIM (0.25ml/kg) IGIM (0.50 ml/kg) IGIV (100 mg/kg) IGIV (200 mg/kg) IGIV (400 mg/kg) Minimum mnab potency (IU/mL) Minimum mnab dose (IU/kg) Calculated serum mnab level (miu/ml) Peak 4-6 hours Equilibrium 4-5 days Trough days [158] [315]
28 IG for measles PEP The recommendations for the use of immunoglobulin products for measles post-exposure prophylaxis were revised in the US in These revised doses of immunoglobulin for measles PEP have been increased from previous recommendations due to a recognition that measles antibody levels have declined over recent years. This is likely due to a much higher proportion of donors with vaccine-only associated measles immunity.
29 Recommended IG dosage for measles PEP Indications Dose Interval before MMR vaccine administration Infants <12months of age Susceptible immunocompetent contacts <30 kg Pregnant women without evidence of immunity Severely immunocompromised persons* 0.5 ml/kg IM (max dose = 15mL) 0.5 ml/kg IM (max dose = 15mL) 6 months 6 months 400 mg/kg IV 8 months and nonpregnant 400 mg/kg IV 8 months AAP. Redbook 30 th ed, 2015
30 PRN titer (IU/mL) Potency of measles neutralizing Abs in IG products (1% IgG concentration) IGIV IGIM IGSC Minimum potency of IGIM Minimum potency of IGIV, IGSC 0.0 A B C D E A F G H I IV IM SC Immunoglobulin Products Kim KH et al. 2015
31 mnab potency in IGIV and IGSC products -Korean study- Route Plasma source Manufacturer mnab potency (IU/mL) Administration dose of IG (IU/kg)* IV Korea A Korea B Japan C D US E SC Germany I IM Korea A Japan F *Administration dose - IM: 0.50mL/kg, IV: 400mg/kg, SC: 200mg/kg G H Kim KH et al. 2015
32 Acute viral hepatitis Hepatitis A (HAV) Fever, malaise, nausea and abdominal discomfort, followed by jaundice a few days later More severe in adults, full recovery may take several months Case-fatality: greater than 2% for those over 40 years of age about 4% for those aged 60 years
33 Hepatitis A, countries or areas at risk
34 Preexposure-prophylaxis of HAV for travelers (to countries with high or intermediate endemicity) Age Younger than 12 mo Recommended prophylaxis IMIG Up to 3 mo of travel, 0.02 ml/kg 3 mo of travel, 0.06 ml/kg (repeat every 5 months) 12 mo through 40 y HepA vaccine 41 y or older HepA vaccine, with or without IMIG Modified from AAP. Redbook 30 th ed, 2015
35 PEP against HAV Time since exposure Age of patient 2 wk Younger than 12 mo 12 mo through 40 y 41 y or older People of any age who are immunocompromised, have chronic liver disease, or contraindication to vaccination > 2 wk Younger than 12 mo 12 mo or older Recommended prophylaxis IMIg, 0.02 ml/kg HepA vaccine IMIG, 0.02 ml/kg, but HepA vaccine can be used if IGIM is unavailable IMIG, 0.02 ml/kg No prophylaxis No prophylaxis, but HepA vaccine may be indicated for ongoing exposure AAP. Redbook 30 th ed, 2015
36 Reported No. of Cases Epidemiology of HAV Republic of Korea, United States, Year
37 Age specific seroprevalence against hepatitis A in Korea, Lee H et al. J Korean Med Sci 2011
38 Evaluation of potencies of IG products against HAV Anti-HAV Ab levels are declining in plasma donors from developed countries. The content of anti-hav IgG and neutralizing Abs was measured by an immunoassay and an end point dilution antibiotic resistance titration assay. Daily decay of plasma anti-hav antibodies was modeled assuming a best-case scenario of complete absorption of 0.02 ml/kg of IG (intramuscular). Tejada-Strop A et al. JAMA Intern Med. 2017
39 Tejada-Strop A et al. JAMA Intern Med. 2017
40 TABLE. Indications and updated dosage recommendations for GamaSTAN S/D human immune globulin for preexposure and postexposure prophylaxis against hepatitis A infection Indication Updated dosage recommendation Preexposure prophylaxis Up to 1 month of travel Up to 2 months of travel 2 months of travel or longer 0.1 ml/kg 0.2 ml/kg 0.2 ml/kg (repeat every 2 months) Postexposure prophylaxis 0.1 ml/kg Nelson NP. MMWR 2017;66(36):
41 Anti-HAV titers in intramuscular IG products -Korean study- Route Plasma source Manufacturer Anti-HAV (IU/mL) IM Korea A 19.7 Japan F 5.5 G 5.5 H 5.5 *Hepatitis A (anti-hav titer) Electrochemiluminescence immunoassay, Cobas 8000 e602 (Roche, Germany) minimum protective level, 10 miu/ml Cho HK et al. presented at Autumn Meeting of KPID, 2014
42 Korea 28.2 Tejada-Strop A et al. JAMA Intern Med. 2017
43 Korea 42.5 Tejada-Strop A et al. JAMA Intern Med. 2017
44 Lee S et al. Transfusion 2017
45 Expected trough levels for Hib, four serogroups of meningococcus in 16 lots of IVIG products from Korea *IVIG 400 mg/kg was assumed to be infused into the patients. Lee S et al. Transfusion 2017
46 Expected trough levels of OIs against 26 serotypes of pneumococci in various IVIG products *IVIG 400 mg/kg was assumed to be infused into the patients. Lee S et al. Transfusion 2017
47 Considering issues Is an antibody potency test for all pathogens absolutely necessary? Serostatus of population (declining antibody titers) Epidemiology of infectious disease Concern for supply Costs Development of efficient and accurate test tools
48 Subcutaneous IG (SCIG) IVIG every 3 4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of SCIG is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for SCIG therapy in patients with antibody deficiencies. Nevertheless, SCIG is NOT available in Korea.
49 Conclusions It is important that various formulations of immunoglobulins are supplied stably to properly respond to various situations and treat patients. Continuous monitoring and quality control of antibody levels in IG preparations is essential for the effective prevention and treatment of infectious diseases. In order to establish appropriate quality control standards, sufficient discussion of clinical physicians, infectious disease epidemiologists, manufacturers, and biopharmaceuticals authorities is required.
Cigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Immune Globulin Subcutaneous [Human] Effective Date... 5/15/2012 Next Review Date.5/15/2013 Coverage Policy Number... 8004 Table of Contents Coverage Policy... 1 General
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More informationMEASLES HEALTH ALERT/ADVISORY. Date: February 5, Dear Colleague:
MEASLES HEALTH ALERT/ADVISORY Date: February 5, 2019 Dear Colleague: Details of situation: Five measles cases, four between the ages of 12 to 21 months, have been reported in three different counties within
More information9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
26 February 2015 EMA/CHMP/BPWP/356950/2013 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Guideline on core SmPC for human normal immunoglobulin for subcutaneous
More informationSCIG: (Immune globulin SQ) Hizentra, Vivaglobin, Gammagard Liquid, Gamunex- C, Gammaked, Hyqvia Page 1 of 6
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 04/1 Revision Date(s): 02/16 Developed By: Medical Criteria Committee Effective Date: 0/01/1 SCIG: (Immune globulin SQ) Hizentra,
More informationImmunity and how vaccines work
Immunity and how vaccines work Dr Mary O Meara National Immunisation Office Objectives of session An understanding of the following principles Overview of immunity Different types of vaccines and vaccine
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationPRIMARY IMMUNODEFICIENCIES CVID MANAGEMENT CVID MANAGEMENT
PRIMARY IMMUNODEFICIENCIES CVID MANAGEMENT CVID MANAGEMENT 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CVID CT IgA IgG IgM IPOPI IVIG SCIG PID Common Variable Immune Deficiency Computerised tomography
More informationVaccines. Vaccines ( continued 1) February 21, 2017 Department of Public Health Sciences
Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 11 Vaccines Past, Present, Future Learning Objectives 1. Identify the various types of vaccines 2. Describe the role of vaccine in
More informationSubcutaneous ImmunoglobulinTherapy A New Way of Permanent Treatment in Primary Immunodeficiencies Gaby Strotmann
Subcutaneous ImmunoglobulinTherapy A New Way of Permanent Treatment in Primary Immunodeficiencies Gaby Strotmann Immunodeficiency Department University Children s Hospital Dr. von Haunersches Kinderspital
More informationClinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid
Clinical Policy: Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy
More informationMeasles: United States, January 1 through June 10, 2011
Measles: United States, January 1 through June 10, 2011 Preeta K. Kutty, MD, MPH Measles, Mumps, Rubella and Polio Team Division of Viral Diseases Centers for Disease Control and Prevention Atlanta, GA
More informationVaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications
Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications Vaccine Prematurity 1 Altered Immunocompetence 2 (excluding human immunodefi ciency virus [HIV] infection)
More informationDisclosure Statement. I have no affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization.
Disclosure Statement I have no affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. 1 What s new with NACI? Dr. Caroline Quach, NACI Chair Dr. Matthew
More informationPrimary Immunodeficiency
Primary Immunodeficiency DiGeorge Syndrome Severe Combined Immunodeficiency SCID X-Linked Agammaglobulinemia Common variable immunodeficiency (CVID) IgA deficiency Hyper- IgM Syndrome Wiskott-Aldrich syndrome
More informationMeasles Update. March 16, 2015 Lisa Miller, MD, MSPH Communicable Disease Branch Chief Lynn Trefren MSN, RN Immunization Branch Chief
Measles Update March 16, 2015 Lisa Miller, MD, MSPH Communicable Disease Branch Chief Lynn Trefren MSN, RN Immunization Branch Chief Colorado Department of Public Health and Environment Presenters have
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationManagement of Vaccine Preventable Diseases in 2016
Management of Vaccine Preventable Diseases in 2016 Teri Moser Woo PhD, CPNP, ARNP, FAANP Disclosures No financial conflicts Objectives Review current child and adolescent vaccination rates in the United
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationNancy Nazaire-Bermal,MD Fellow PPS, PIDSP
DISEASE CONTAINMENT IN PEDIATRICS: PRACTICAL APPLICATIONS SETTING UP THE FINAL DEFENSE Nancy Nazaire-Bermal,MD Fellow PPS, PIDSP Objectives To provide practical and rational approach in postexposure chemoprophylaxis
More informationCOMMON VARIABLE IMMUNODEFICIENCY
COMMON VARIABLE IMMUNODEFICIENCY This booklet is intended for use by patients and their families and should not replace advice from a clinical immunologist. 1 COMMON VARIABLE IMMUNODEFICIENCY Also available
More informationSubcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency
Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.
More informationImmunization-Preventable Outbreaks, Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014
Immunization-Preventable Outbreaks, 2014 Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency May 5, 2014 Outbreaks to Cover Meningococcus group B Pertussis Mumps
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Chickenpox Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Caused
More informationHEALTH ADVISORY: MEASLES EXPOSURES IN NEW YORK STATE
December 11, 2018 To: Health Care Providers, Hospitals, Emergency Departments, Dental Providers, and Local Health Departments From: New York State Department of Health, Bureau of Immunization HEALTH ADVISORY:
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Chickenpox Caused
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More informationPlease read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture. Chapters 9, 17 and 8 for next Friday s lectures
Valerie Daggett Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture Chapters 9, 17 and 8 for next Friday s lectures ppt files for first 2 lectures Past exams Principles of
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GAMMANORM, 165 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg) Human
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationIndication Dosage Instruction Measles 0.25 ml/kg Administer within 6 days of exposure.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAMASTAN safely and effectively. See full prescribing information for GAMASTAN. GAMASTAN (immune
More informationIg Therapy: One Size Does Not Fit All
Ig Therapy: One Size Does Not Fit All Carla Duff, CPNP, MSN, IgCN Advanced Registered Nurse Practitioner University of South Florida Division of Allergy, Immunology, and Rheumatology 1 Objectives Understand
More informationSV/SPC/ SUMMARY OF PRODUCT CHARACTERISTICS
SV/SPC/20160315 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GammaQuin 160 g/l solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg)
More informationHepatitis B Immune Globulin Biological Page
Hepatitis B Immune Globulin Biological Page Section 7: Biological Product Information Standard #: 07.233 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide
More informationSubcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Mai Thị Bích Ngọc
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases Mai Thị Bích Ngọc Background Primary immunodeficiency diseases (PIDD): group of over 150 disorders
More informationHepatitis A Surveillance Protocol
Provider Responsibilities 1. Report all cases to your local health department within the timeframe indicated: Sporadic case of - should be reported within 24 hours of diagnosis. Outbreaks of - should be
More information5/13/2015 TODAY S TOPICS SURVEILLANCE, REPORTING AND CONTROL OF VACCINE PREVENTABLE DISEASES 2015
SURVEILLANCE, REPORTING AND CONTROL OF VACCINE PREVENTABLE DISEASES 2015 20 th Annual Massachusetts Adult Immunization Conference April 14, 2015 Hillary Johnson, MHS Meagan Burns, MPH Epidemiologists Epidemiology
More informationNYS Trends in Vaccine Preventable Disease Control
NYS Trends in Vaccine Preventable Disease Control Cindy Schulte, BSN, RN Bureau of Immunization 518-473-4437 crs01@health.state.ny.us 1 Objectives Participants will be able to identify disease outbreaks
More informationVaccines. Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University. Outline
Vaccines Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Outline Public health impact of vaccines Historical perspective Active vs. Passive Immunization Immune system
More informationIMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine
IMMUNIZATION PROTOCOLS FOR PHARMACISTS VARICELLA Live Virus Vaccine I. ORDER: 1. Screen for contraindications and evidence of immunity (Section VII.K.) 2. Provide a current Vaccine Information Statement
More informationIVIg. Treatment With Privigen. Proven protection Designed for stability. Your guide to USED IN US HOSPITALS SINCE 2010
# 1 IVIg USED IN US HOSPITALS SINCE 2010 Your guide to Treatment With Privigen For people with primary immunodeficiency (PI) Proven protection Designed for stability Please see full Important Safety Information
More informationEpidemiologic Characteristics of Recent Measles Outbreaks in ROK
Epidemiologic Characteristics of Recent Measles Outbreaks in ROK Park Ok Director, Division of VPD control and NIP, KCDC Immunization History for MMR Vaccine 1980 MMR was introduced 1983 MMR was included
More informationRecommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman
Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute
More informationMeasles 2015: What We Need to Know
Faculty Measles 2015: What We Need to Know Karen Landers, MD, FAAP Assistant State Health Officer Tuberculosis Control and Immunization Alabama Department of Public Health Produced by the Alabama Department
More informationTo provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).
Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from
More informationGuideline for the immunization of HIV infected persons in Sri Lanka
DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital
More informationImmunization for Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients
Immunization for Adult Recipients January 4, 201 Immunization for Adult Hematopoietic Stem Cell Transplant () Recipients Revision Date: January 4, 201 Note: This guide is meant to supplement existing recommendations
More informationInfection Prophylaxis Including Vaccination
Infection Prophylaxis Including Vaccination For the Consensus Panel 1 Elias Anaissie, MD. Myeloma Institute for Research & Therapy Little Rock, AR, USA Paris, May 3-6, 2011 Infection Prophylaxis including
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationViral Hepatitis - Historical Perspective
Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D F, G,? other C Parenterally transmitted Before the discovery of hepatitis A virus (HAV) and
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationF.A.S.N. annual conference 2009 Alix Casler, M.D., F.A.A.P. Orlando, FL
F.A.S.N. annual conference 2009 Alix Casler, M.D., F.A.A.P. Orlando, FL Immunization Update for School Nurses Overview of Vaccine Preventable Diseases FL Vaccine Requirements Medical Guidelines vs State
More informationHepatitis A Case Investigation and Outbreak Response. Terrie Whitfield LPN Public Health Representative
Hepatitis A Case Investigation and Outbreak Response Terrie Whitfield LPN Public Health Representative Training Objectives Provide an overview of HAV epidemiology Present reporting criteria and HAV case
More informationIt IS a Small World After All: The Public Health Impact and Immunologic Assessment of a Disneyland Measles Case in El Paso County, Colorado
It IS a Small World After All: The Public Health Impact and Immunologic Assessment of a Disneyland Measles Case in El Paso County, Colorado Panel: Robyn Espy, M.P.H, Marigny Klaber, M.Sc., Shannon Rowe,
More informationHealthcare Personnel Immunization. Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville
Healthcare Personnel Immunization Ruth Carrico PhD RN FSHEA CIC Associate Professor Division of Infectious Diseases University of Louisville Disclosures Funding provided by the U. S. Department of Homeland
More informationVIRAL HEPATITIS. Monique Punsalan Angelie Regala James Rondal
VIRAL HEPATITIS Monique Punsalan Angelie Regala James Rondal PRIMARY VIRAL HEPATITIS INCUBATION (DAYS) HEPATITIS A HEPATITIS B HEPATITIS C HEPATITIS D HEPATITITS E 15-45, MEAN 30 30-180, MEAN 60-90 15-160,
More informationHepatitis A Virus Infections
Hepatitis A Virus Infections Robert L. Brawley, MD, MPH, FSHEA Chief, Infectious Disease Branch Division of Epidemiology and Health Planning Kentucky Department for Public Health Objectives Discuss the
More informationKEDRAB Rabies Immune Globulin (Human) Solution for intramuscular injection Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEDRAB safely and effectively. See full prescribing information for KEDRAB. KEDRAB Rabies Immune
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationImmunization for Child Hematopoietic Stem Cell Transplant (HSCT) Recipients
Immunization for Child Recipients January 4, 201 Immunization for Child Hematopoietic Stem Cell Transplant () Recipients Revision Date: January 4, 201 Note: This guide is meant to supplement existing recommendations
More informationVACCINE-PREVENTABLE DISEASE EPIDEMIOLOGY
VACCINE-PREVENTABLE DISEASE EPIDEMIOLOGY Massachusetts Immunization Action Partnership (MIAP) Conference October 18, 2018 Nancy Harrington nancy.harrington@dph.state.ma.us Presenter Disclosure Information
More informationEMPLOYEE HEALTH TABLE OF CONTENTS
EMPLOYEE HEALTH TABLE OF CONTENTS PHYSICAL ASSESSMENT.2 REPORTING EMPLOYEE INFECTIONS...3 SUMMARY OF IMPORTANT RECOMMENDATIONS AND WORK RESTRICTIONS FOR PERSONNEL WITH INFECTIOUS DISEASES.4 HEPATITIS B
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Immune Globulin Subcutaneous [Human] Effective Date......4/15/2016 Next Review Date...4/15/2017 Coverage Policy Number... 8004 Table of Contents Coverage
More informationProblem 7 Unit 6 Clinical: Primary immunodeficiency
Problem 7 Unit 6 Clinical: Primary immunodeficiency THE IMMUNE SYSTEM - Function: recognizing pathogens (foreign non-self antigens) and organizing a defense response against them by facilitating destruction
More informationIMMUNIZATION IN CHILDREN WITH CANCER
SIOP PODC Supportive Care Education Presentation Date: 05 th September 2014 Recording Link at www.cure4kids.org: http://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p2xokm5imdj Email: ahmed.naqvi@sickkids.ca
More informationAutoimmunity and Primary Immune Deficiency
Autoimmunity and Primary Immune Deficiency Mark Ballow, MD Division of Allergy & Immunology USF Morsani School of Medicine Johns Hopkins All Children s Hospital St Petersburg, FL The Immune System What
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationSplenectomy Vaccine Protocol PIDPIC
Splenectomy Vaccine Protocol PIDPIC 6.24.14 Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid tissues where B cells are educated against encapsulated
More informationWisconsin physicians, other clinicians, infection control professionals, local health department directors in Wisconsin
DIVISION OF PUBLIC HEALTH 1 WEST WILSON STREET P O BOX 2659 Jim Doyle MADISON WI 53701-2659 Governor State of Wisconsin 608-266-1251 Kevin R. Hayden FAX: 608-267-2832 Secretary TTY: 888-701-1253 Department
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More informationImmunization Update: What s New?
Immunization Update: What s New? Joseph A. Bocchini, Jr. MD, FAAP Professor and Chairman Department of Pediatrics Louisiana State University Health Sciences Center Shreveport Red Stick Potpourri LA Chapter-American
More informationOPTIMIZING VACCINE IMMUNITY IN THE IMMUNOCOMRPOMISED PEDIATRIC PATIENT
OPTIMIZING VACCINE IMMUNITY IN THE IMMUNOCOMRPOMISED PEDIATRIC PATIENT Victoria A. Statler, M.D., M.Sc. Division of Pediatric Infectious Diseases Pediatric Transplant Infectious Diseases University of
More informationFrom: Plasma Protein Therapeutics Association (PPTA)
Polyvalent Human Immunoglobulins Application for reinstatement to the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary statement of the proposal for inclusion, change or deletion
More informationMeasles, Mumps and Rubella. Ch 10, 11 & 12
Measles, Mumps and Rubella Ch 10, 11 & 12 Measles Highly contagious viral illness First described in 7th century Near universal infection of childhood in prevaccination era Remains the leading cause of
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationViral Vaccines I 5/17/04 LECTURE OUTLINE I. CASE HISTORY
Viral Vaccines I I. CASE HISTORY LECTURE OUTLINE 5/17/04 A 22-year-old Amish woman became ill with a headache, fever, and generalized muscle pain. Two days later, she developed right and then left lower
More informationPackage leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration
: Information for the user HEPATECT CP 50 IU/ml solution for infusion Human hepatitis B immunoglobulin for intravenous administration Read all of this leaflet carefully before you start using this medicine
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More informationThe Continued Need for Immunizations in Top Ten Causes of Death in the U.S., 1900 vs Common Questions about Vaccines
The Continued Need for Immunizations in 2016 Stephanie Schauer, Ph.D. Program Manager, Immunization Program April 13, 2016 Ten Great Public Health Achievements United States, 1900-1999 MMWR 1999 Control
More informationThe Continued Need for Immunizations in 2016
The Continued Need for Immunizations in 2016 Stephanie Schauer, Ph.D. Program Manager, Immunization Program April 13, 2016 Wisconsin Department of Health Services Ten Great Public Health Achievements United
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT UMAN BIG 180 IU/ml Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. UMAN BIG 180 IU/1
More informationStudy Events 2. Consent Information 3. Family History 5. Registry Visit 8. Visit Information 11. Vitals / Measures 13. Clinical History 15
Study Events 2 Consent Information 3 Family History 5 Registry Visit 8 Visit Information 11 Vitals / Measures 13 Clinical History 15 Immunizations, Infusions, Transfusions 31 Medications & Supplements
More informationVACCINATION PASSIVE IMMUNITY
VACCINATION Immunization is one of the most beneficial and cost-effective disease prevention measures. As a result of effective and safe vaccines, smallpox has been eradicated, polio is close to worldwide
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Human Medicines Evaluation Unit London, 27 April 2006 CPMP/BPWG/4027/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CORE SPC FOR HUMAN PLASMA DERIVED
More informationVACCINATION. C. Mhorag Hay
C. Mhorag Hay VACCINATION What you need to know: 1. The nature and function of passive and active immunization 2. The role of humoral and cellular immunity in vaccination 3. The types of vaccines currently
More informationExpanded Programme on Immunization (EPI):
Expanded Programme on Immunization (EPI): Introduction Four to five million annual deaths could be prevented by 2015 through sustained and appropriate immunization efforts, backed by financial support.
More informationGuidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
More informationHOW DO VACCINES WORK?
Official Topic from UpToDate, the clinical decision support resource accessed by 700,000+ clinicians worldwide. Available via the web and mobile devices, subscribe to UpToDate at www.uptodate.com/store.
More information2013 National Treatment Survey. Immune Deficiency Foundation
2013 National Treatment Survey Immune Deficiency Foundation IDF 2013 Treatment Survey Mail-based, pencil & paper survey Over 75 Main questions Survey in the field December 2013-March 2014 IDF mail invitation
More informationIgG subclass deficiencies
IgG subclass deficiencies hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on IgG subclass deficiencies. It has been produced by the PID UK Medical Advisory
More informationImmunity & How Vaccines Work
Immunity & How Vaccines Work Immunisation Study Day 30 th November 2016 Talk given today by Dr. Mary Fitzgerald Learning outcome To be able to describe in outline the immune system and how vaccines work
More informationTetanus Immune Globulin (Human) Biological Page
Tetanus Immune Globulin (Human) Biological Page Section 7: Biological Product Information Standard #: 07.322 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationManchester Royal Infirmary. Antibody Deficiency. Information For Patients
Manchester Royal Infirmary Antibody Deficiency Information For Patients 1 What is Immunodeficiency? Immunodeficiency is the name given to the condition of having a faulty immune system which reduces your
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationMeasles rev Jan 2018
rev Jan 2018 BASIC EPIDEMIOLOGY Infectious Agent The measles virus-a single-stranded, RNA-encoded paramyxovirus Transmission Virus is spread directly from person to person by inhalation of suspended droplet
More informationManual for the Surveillance of Vaccine-Preventable Diseases
VPD Surveillance Manual Manual for the Surveillance of Vaccine-Preventable Diseases Edited by Sandra W. Roush, MT, MPH Linda M. Baldy, MPH National Center for Immunization and Respiratory Diseases Centers
More informationSECTION 14 - PRINCIPLES OF IMMUNOLOGY TABLE OF CONTENTS
SECTION 14 - PRINCIPLES OF IMMUNOLOGY TABLE OF CONTENTS 1.0 THE IMMUNE SYSTEM... 1 1.1 INTRODUCTION... 1 1.2 CELLS OF THE IMMUNE SYSTEM... 1 1.3 LYMPHATIC SYSTEM... 1 1.4 TYPES OF IMMUNITY (SEE FIGURE
More information